Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

A Systematic Review of the Clinical Implementation of Pelvic Magnetic Resonance Imaging-Only Planning for External Beam Radiation Therapy.

Bird D, Henry AM, Sebag-Montefiore D, Buckley DL, Al-Qaisieh B, Speight R.

Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):479-492. doi: 10.1016/j.ijrobp.2019.06.2530. Epub 2019 Jul 2. Review.

2.

MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation.

Sdelci S, Rendeiro AF, Rathert P, You W, Lin JG, Ringler A, Hofstätter G, Moll HP, Gürtl B, Farlik M, Schick S, Klepsch F, Oldach M, Buphamalai P, Schischlik F, Májek P, Parapatics K, Schmidl C, Schuster M, Penz T, Buckley DL, Hudecz O, Imre R, Wang SY, Maric HM, Kralovics R, Bennett KL, Müller AC, Mechtler K, Menche J, Bradner JE, Winter GE, Klavins K, Casanova E, Bock C, Zuber J, Kubicek S.

Nat Genet. 2019 Jun;51(6):990-998. doi: 10.1038/s41588-019-0413-z. Epub 2019 May 27.

PMID:
31133746
3.

Analytical validation of single-kidney glomerular filtration rate and split renal function as measured with magnetic resonance renography.

Basak S, Buckley DL, Chrysochou C, Banerji A, Vassallo D, Odudu A, Kalra PA, Sourbron SP.

Magn Reson Imaging. 2019 Jun;59:53-60. doi: 10.1016/j.mri.2019.03.005. Epub 2019 Mar 6. No abstract available.

PMID:
30849485
4.

Incidental significant arrhythmia in scleroderma associates with cardiac magnetic resonance measure of fibrosis and hs-TnI and NT-proBNP.

Bissell LA, Dumitru RB, Erhayiem B, Abignano G, Fent G, Kidambi A, Donica H, Burska A, Del Galdo F, Biglands J, Buckley DL, Greenwood JP, Plein S, Graham L, Buch MH.

Rheumatology (Oxford). 2019 Jul 1;58(7):1221-1226. doi: 10.1093/rheumatology/key430.

5.

A functional form for a representative individual arterial input function measured from a population using high temporal resolution DCE MRI.

Georgiou L, Wilson DJ, Sharma N, Perren TJ, Buckley DL.

Magn Reson Med. 2019 Mar;81(3):1955-1963. doi: 10.1002/mrm.27524. Epub 2018 Sep 26.

PMID:
30257053
6.

Shutter-speed dynamic contrast-enhanced MRI: Is it fit for purpose?

Buckley DL.

Magn Reson Med. 2019 Feb;81(2):976-988. doi: 10.1002/mrm.27456. Epub 2018 Sep 19.

PMID:
30230007
7.

Mutant NPM1 Maintains the Leukemic State through HOX Expression.

Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, Gionfriddo I, Mezzasoma F, Milano F, Nabet B, Buckley DL, Kornblau SM, Lin CY, Sportoletti P, Martelli MP, Falini B, Goodell MA.

Cancer Cell. 2018 Sep 10;34(3):499-512.e9. doi: 10.1016/j.ccell.2018.08.005.

8.

Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.

Liu S, Yosief HO, Dai L, Huang H, Dhawan G, Zhang X, Muthengi AM, Roberts J, Buckley DL, Perry JA, Wu L, Bradner JE, Qi J, Zhang W.

J Med Chem. 2018 Sep 13;61(17):7785-7795. doi: 10.1021/acs.jmedchem.8b00765. Epub 2018 Aug 30.

9.

Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.

Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Muñoz-Guardiola P, Diéguez-Martínez N, Deng X, Hao M, Massefski W, Fedorov O, Offei-Addo NK, Park PM, Dai L, DiBona A, Becht K, Kim ND, McKeown MR, Roberts JM, Zhang J, Sim T, Alessi DR, Bradner JE, Lizcano JM, Blacklow SC, Qi J, Xu X, Gray NS.

ACS Chem Biol. 2018 Sep 21;13(9):2438-2448. doi: 10.1021/acschembio.7b00638. Epub 2018 Aug 31.

PMID:
30102854
10.

Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma.

Xu L, Chen Y, Mayakonda A, Koh L, Chong YK, Buckley DL, Sandanaraj E, Lim SW, Lin RY, Ke XY, Huang ML, Chen J, Sun W, Wang LZ, Goh BC, Dinh HQ, Kappei D, Winter GE, Ding LW, Ang BT, Berman BP, Bradner JE, Tang C, Koeffler HP.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5086-E5095. doi: 10.1073/pnas.1712363115. Epub 2018 May 15.

11.

The dTAG system for immediate and target-specific protein degradation.

Nabet B, Roberts JM, Buckley DL, Paulk J, Dastjerdi S, Yang A, Leggett AL, Erb MA, Lawlor MA, Souza A, Scott TG, Vittori S, Perry JA, Qi J, Winter GE, Wong KK, Gray NS, Bradner JE.

Nat Chem Biol. 2018 May;14(5):431-441. doi: 10.1038/s41589-018-0021-8. Epub 2018 Mar 26.

12.

Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands.

Gechijian LN, Buckley DL, Lawlor MA, Reyes JM, Paulk J, Ott CJ, Winter GE, Erb MA, Scott TG, Xu M, Seo HS, Dhe-Paganon S, Kwiatkowski NP, Perry JA, Qi J, Gray NS, Bradner JE.

Nat Chem Biol. 2018 Apr;14(4):405-412. doi: 10.1038/s41589-018-0010-y. Epub 2018 Mar 5.

13.

Acute Pharmacologic Degradation of a Stable Antigen Enhances Its Direct Presentation on MHC Class I Molecules.

Moser SC, Voerman JSA, Buckley DL, Winter GE, Schliehe C.

Front Immunol. 2018 Jan 8;8:1920. doi: 10.3389/fimmu.2017.01920. eCollection 2017.

14.

Renal Cell Carcinoma Perfusion before and after Radiofrequency Ablation Measured with Dynamic Contrast Enhanced MRI: A Pilot Study.

Wah TM, Sourbron S, Wilson DJ, Magee D, Gregory WM, Selby PJ, Buckley DL.

Diagnostics (Basel). 2018 Jan 8;8(1). pii: E3. doi: 10.3390/diagnostics8010003.

15.
16.

YY1 Is a Structural Regulator of Enhancer-Promoter Loops.

Weintraub AS, Li CH, Zamudio AV, Sigova AA, Hannett NM, Day DS, Abraham BJ, Cohen MA, Nabet B, Buckley DL, Guo YE, Hnisz D, Jaenisch R, Bradner JE, Gray NS, Young RA.

Cell. 2017 Dec 14;171(7):1573-1588.e28. doi: 10.1016/j.cell.2017.11.008. Epub 2017 Dec 7.

17.

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Huang HT, Dobrovolsky D, Paulk J, Yang G, Weisberg EL, Doctor ZM, Buckley DL, Cho JH, Ko E, Jang J, Shi K, Choi HG, Griffin JD, Li Y, Treon SP, Fischer ES, Bradner JE, Tan L, Gray NS.

Cell Chem Biol. 2018 Jan 18;25(1):88-99.e6. doi: 10.1016/j.chembiol.2017.10.005. Epub 2017 Nov 9.

18.

MELK is not necessary for the proliferation of basal-like breast cancer cells.

Huang HT, Seo HS, Zhang T, Wang Y, Jiang B, Li Q, Buckley DL, Nabet B, Roberts JM, Paulk J, Dastjerdi S, Winter GE, McLauchlan H, Moran J, Bradner JE, Eck MJ, Dhe-Paganon S, Zhao JJ, Gray NS.

Elife. 2017 Sep 19;6. pii: e26693. doi: 10.7554/eLife.26693.

19.

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W.

Nat Med. 2017 Sep;23(9):1063-1071. doi: 10.1038/nm.4378. Epub 2017 Aug 14.

20.

BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.

Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE, Vittori S, Reyes JM, di Iulio J, Souza A, Ott CJ, Roberts JM, Zeid R, Scott TG, Paulk J, Lachance K, Olson CM, Dastjerdi S, Bauer S, Lin CY, Gray NS, Kelliher MA, Churchman LS, Bradner JE.

Mol Cell. 2017 Jul 6;67(1):5-18.e19. doi: 10.1016/j.molcel.2017.06.004. Epub 2017 Jun 29.

21.

Kidney volume to GFR ratio predicts functional improvement after revascularization in atheromatous renal artery stenosis.

Chrysochou C, Green D, Ritchie J, Buckley DL, Kalra PA.

PLoS One. 2017 Jun 8;12(6):e0177178. doi: 10.1371/journal.pone.0177178. eCollection 2017.

22.

Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.

Remillard D, Buckley DL, Paulk J, Brien GL, Sonnett M, Seo HS, Dastjerdi S, Wühr M, Dhe-Paganon S, Armstrong SA, Bradner JE.

Angew Chem Int Ed Engl. 2017 May 15;56(21):5738-5743. doi: 10.1002/anie.201611281. Epub 2017 Apr 18.

23.

Estimating breast tumor blood flow during neoadjuvant chemotherapy using interleaved high temporal and high spatial resolution MRI.

Georgiou L, Sharma N, Broadbent DA, Wilson DJ, Dall BJ, Gangi A, Buckley DL.

Magn Reson Med. 2018 Jan;79(1):317-326. doi: 10.1002/mrm.26684. Epub 2017 Apr 3.

24.

Transcription control by the ENL YEATS domain in acute leukaemia.

Erb MA, Scott TG, Li BE, Xie H, Paulk J, Seo HS, Souza A, Roberts JM, Dastjerdi S, Buckley DL, Sanjana NE, Shalem O, Nabet B, Zeid R, Offei-Addo NK, Dhe-Paganon S, Zhang F, Orkin SH, Winter GE, Bradner JE.

Nature. 2017 Mar 9;543(7644):270-274. doi: 10.1038/nature21688. Epub 2017 Mar 1.

25.

Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET-BRET.

Koblan LW, Buckley DL, Ott CJ, Fitzgerald ME, Ember SW, Zhu JY, Liu S, Roberts JM, Remillard D, Vittori S, Zhang W, Schonbrunn E, Bradner JE.

ChemMedChem. 2016 Dec 6;11(23):2575-2581. doi: 10.1002/cmdc.201600502. Epub 2016 Nov 15.

PMID:
27862999
26.

Imaging biomarker roadmap for cancer studies.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC.

Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. doi: 10.1038/nrclinonc.2016.162. Epub 2016 Oct 11. Review.

28.

Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.

Gustafson JL, Neklesa TK, Cox CS, Roth AG, Buckley DL, Tae HS, Sundberg TB, Stagg DB, Hines J, McDonnell DP, Norris JD, Crews CM.

Angew Chem Int Ed Engl. 2015 Aug 10;54(33):9659-62. doi: 10.1002/anie.201503720. Epub 2015 Jun 17.

29.

Catalytic in vivo protein knockdown by small-molecule PROTACs.

Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, Mulholland KE, Routly N, Buckley DL, Gustafson JL, Zinn N, Grandi P, Shimamura S, Bergamini G, Faelth-Savitski M, Bantscheff M, Cox C, Gordon DA, Willard RR, Flanagan JJ, Casillas LN, Votta BJ, den Besten W, Famm K, Kruidenier L, Carter PS, Harling JD, Churcher I, Crews CM.

Nat Chem Biol. 2015 Aug;11(8):611-7. doi: 10.1038/nchembio.1858. Epub 2015 Jun 10.

30.

HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

Buckley DL, Raina K, Darricarrere N, Hines J, Gustafson JL, Smith IE, Miah AH, Harling JD, Crews CM.

ACS Chem Biol. 2015 Aug 21;10(8):1831-7. doi: 10.1021/acschembio.5b00442. Epub 2015 Jun 23.

31.

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.

Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE.

Science. 2015 Jun 19;348(6241):1376-81. doi: 10.1126/science.aab1433. Epub 2015 May 21.

32.

Sensitivity of quantitative myocardial dynamic contrast-enhanced MRI to saturation pulse efficiency, noise and t1 measurement error: Comparison of nonlinearity correction methods.

Broadbent DA, Biglands JD, Ripley DP, Higgins DM, Greenwood JP, Plein S, Buckley DL.

Magn Reson Med. 2016 Mar;75(3):1290-300. doi: 10.1002/mrm.25726. Epub 2015 May 6.

33.

Biased multicomponent reactions to develop novel bromodomain inhibitors.

McKeown MR, Shaw DL, Fu H, Liu S, Xu X, Marineau JJ, Huang Y, Zhang X, Buckley DL, Kadam A, Zhang Z, Blacklow SC, Qi J, Zhang W, Bradner JE.

J Med Chem. 2014 Nov 13;57(21):9019-27. doi: 10.1021/jm501120z. Epub 2014 Oct 31.

34.

KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer.

Singel SM, Cornelius C, Zaganjor E, Batten K, Sarode VR, Buckley DL, Peng Y, John GB, Li HC, Sadeghi N, Wright WE, Lum L, Corson TW, Shay JW.

Neoplasia. 2014 Mar;16(3):247-56, 256.e2. doi: 10.1016/j.neo.2014.03.008.

35.

Establishment of the National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) Biomarker Support Network.

Williams KJ, Buckley DL, Jones GD.

Clin Oncol (R Coll Radiol). 2014 Jun;26(6):356. doi: 10.1016/j.clon.2014.02.009. Epub 2014 Mar 13. No abstract available.

PMID:
24630609
36.

Gadofosveset-based biomarker of tissue albumin concentration: Technical validation in vitro and feasibility in vivo.

Richardson OC, Bane O, Scott ML, Tanner SF, Waterton JC, Sourbron SP, Carroll TJ, Buckley DL.

Magn Reson Med. 2015 Jan;73(1):244-53. doi: 10.1002/mrm.25128. Epub 2014 Feb 11.

37.

Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system.

Buckley DL, Crews CM.

Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2312-30. doi: 10.1002/anie.201307761. Epub 2014 Jan 23. Review.

38.

Functional, anatomical, and molecular investigation of the cardiac conduction system and arrhythmogenic atrioventricular ring tissue in the rat heart.

Atkinson AJ, Logantha SJ, Hao G, Yanni J, Fedorenko O, Sinha A, Gilbert SH, Benson AP, Buckley DL, Anderson RH, Boyett MR, Dobrzynski H.

J Am Heart Assoc. 2013 Dec 19;2(6):e000246. doi: 10.1161/JAHA.113.000246.

39.

Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: a feasibility study.

Mason J, Al-Qaisieh B, Bownes P, Wilson D, Buckley DL, Thwaites D, Carey B, Henry A.

Brachytherapy. 2014 Mar-Apr;13(2):137-45. doi: 10.1016/j.brachy.2013.10.011. Epub 2013 Nov 20.

PMID:
24268487
40.

Prediction and assessment of responses to renal artery revascularization with dynamic contrast-enhanced magnetic resonance imaging: a pilot study.

Lim SW, Chrysochou C, Buckley DL, Kalra PA, Sourbron SP.

Am J Physiol Renal Physiol. 2013 Sep 1;305(5):F672-8. doi: 10.1152/ajprenal.00007.2013. Epub 2013 Jun 26.

41.

Classic models for dynamic contrast-enhanced MRI.

Sourbron SP, Buckley DL.

NMR Biomed. 2013 Aug;26(8):1004-27. doi: 10.1002/nbm.2940. Epub 2013 May 15. Review.

PMID:
23674304
42.

The effects of cryoablation on renal cell carcinoma perfusion and glomerular filtration rate measured using dynamic contrast-enhanced MRI: a feasibility study.

Chapman SJ, Wah TM, Sourbron SP, Buckley DL.

Clin Radiol. 2013 Sep;68(9):887-94. doi: 10.1016/j.crad.2013.03.015. Epub 2013 Apr 29.

PMID:
23639366
43.

Myocardial blood flow at rest and stress measured with dynamic contrast-enhanced MRI: comparison of a distributed parameter model with a Fermi function model.

Broadbent DA, Biglands JD, Larghat A, Sourbron SP, Radjenovic A, Greenwood JP, Plein S, Buckley DL.

Magn Reson Med. 2013 Dec;70(6):1591-7. doi: 10.1002/mrm.24611. Epub 2013 Feb 15.

44.

Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface.

Van Molle I, Thomann A, Buckley DL, So EC, Lang S, Crews CM, Ciulli A.

Chem Biol. 2012 Oct 26;19(10):1300-12. doi: 10.1016/j.chembiol.2012.08.015.

45.

Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α.

Buckley DL, Gustafson JL, Van Molle I, Roth AG, Tae HS, Gareiss PC, Jorgensen WL, Ciulli A, Crews CM.

Angew Chem Int Ed Engl. 2012 Nov 12;51(46):11463-7. doi: 10.1002/anie.201206231. Epub 2012 Oct 12. No abstract available.

46.

Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging.

Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, Chenevert TL, Collins DJ, Jackson A, Lomas D, Whitcher B, Clarke L, Plummer R, Judson I, Jones R, Alonzi R, Brunner T, Koh DM, Murphy P, Waterton JC, Parker G, Graves MJ, Scheenen TW, Redpath TW, Orton M, Karczmar G, Huisman H, Barentsz J, Padhani A; Experimental Cancer Medicine Centres Imaging Network Steering Committee.

Eur Radiol. 2012 Jul;22(7):1451-64. doi: 10.1007/s00330-012-2446-x. Epub 2012 May 7.

PMID:
22562143
47.

Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction.

Buckley DL, Van Molle I, Gareiss PC, Tae HS, Michel J, Noblin DJ, Jorgensen WL, Ciulli A, Crews CM.

J Am Chem Soc. 2012 Mar 14;134(10):4465-8. doi: 10.1021/ja209924v. Epub 2012 Feb 27.

48.

Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability.

Sourbron SP, Buckley DL.

Phys Med Biol. 2012 Jan 21;57(2):R1-33. doi: 10.1088/0031-9155/57/2/R1. Epub 2011 Dec 15. Review.

PMID:
22173205
49.

Overcoming the low relaxivity of gadofosveset at high field with spin locking.

Richardson OC, Scott ML, Tanner SF, Waterton JC, Buckley DL.

Magn Reson Med. 2012 Oct;68(4):1234-8. doi: 10.1002/mrm.23316. Epub 2011 Dec 9.

50.

BOLD imaging: a potential predictive biomarker of renal functional outcome following revascularization in atheromatous renovascular disease.

Chrysochou C, Mendichovszky IA, Buckley DL, Cheung CM, Jackson A, Kalra PA.

Nephrol Dial Transplant. 2012 Mar;27(3):1013-9. doi: 10.1093/ndt/gfr392. Epub 2011 Aug 19.

PMID:
21856759

Supplemental Content

Loading ...
Support Center